IBIO, INC. Form 10-Q/A: Amended quarterly report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-11-17: Form 10-Q/A; Period of report 2025-09-30; Description 10-Q/A; Document ibio-20250930x10qa.htm.
- 2023-05-19: Form 10-Q/A; Period of report 2022-12-31; Description 10-Q/A; Document ibio-20221231x10qa.htm.
- 2015-02-24: Form 10-Q/A; Period of report 2014-12-31; Description 10-Q/A; Document v402610_10qa.htm.
- 2010-02-17: Form 10-Q/A; Period of report 2009-09-30; Description Quarterly report; Document c60349_10qa.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-11-17 | 10-Q/A | 2025-09-30 | 10-Q/A | ibio-20250930x10qa.htm |
| 2023-05-19 | 10-Q/A | 2022-12-31 | 10-Q/A | ibio-20221231x10qa.htm |
| 2015-02-24 | 10-Q/A | 2014-12-31 | 10-Q/A | v402610_10qa.htm |
| 2010-02-17 | 10-Q/A | 2009-09-30 | Quarterly report | c60349_10qa.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |